Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lac

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Lac. Displaying page 1 of 1.
    EudraCT Number: 2020-001177-78 Sponsor Protocol Number: APHP191008 Start Date*: 2021-02-25
    Sponsor Name:University of Utah
    Full Title: Certolizumab to Prevent Pregnancy Complications in High-Risk Patients with APS or SLE
    Medical condition: Pregnant women with Antiphospholipid Syndrom (APS) and Lupus Antocoagulant (LAC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002817 Antiphospholipid syndrome PT
    20.1 100000004848 10058347 Lupus anticoagulant positive LLT
    20.0 100000004848 10058355 Lupus anticoagulant LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014344-11 Sponsor Protocol Number: prot-001-2009 Start Date*: 2010-06-02
    Sponsor Name:Imperial College London
    Full Title: Neuroprotective effects of hypothermia combined with inhaled xenon following perinatal asphyxia - the TOBY Xe trial
    Medical condition: Neonatal asphyxial encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    12 10028946 neonatal hypoxia and asphyxia SOC
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000574-40 Sponsor Protocol Number: PSP-CoQ10 Start Date*: 2006-04-24
    Sponsor Name:Kompetenznetz Parkinson e.V.
    Full Title: Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon®
    Medical condition: PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 10...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002636-82 Sponsor Protocol Number: OTL-200-07 Start Date*: 2019-12-02
    Sponsor Name:Orchard Therapeutics (Europe) Limited
    Full Title: An open label, non-randomised trial to evaluate the safety and efficacy of a single infusion of OTL-200 in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)
    Medical condition: Metachromatic Leukodystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10067609 Metachromatic leukodystrophy PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001316-76 Sponsor Protocol Number: D9612L00109 Start Date*: 2006-07-20
    Sponsor Name:AstraZeneca GmbH
    Full Title: A randomized, open, parallel-group, multi-centre, phase IV study to evaluate the efficacy of three different patient management strategies with and without esomeprazole 20 mg during a 3 months main...
    Medical condition: Symptoms thought to be gastroesophageal reflux disease (GERD)-related
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004265-25 Sponsor Protocol Number: 2-STEP Start Date*: 2015-04-15
    Sponsor Name:University Medical Centre Utrecht
    Full Title: 2-STEP: A single-centre, phase II study to evaluate the safety, tolerability and pharmacokinetics of 2-Iminobiotin (2-IB) in neonates with gestational age of ≥36 weeks with moderate to severe perin...
    Medical condition: Perinatal asphyxia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10003500 Asphyxia neonatal LLT
    19.0 100000004855 10004943 Birth asphyxia LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001094-25 Sponsor Protocol Number: PHEMI Start Date*: 2019-09-12
    Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
    Full Title: Phenylbutyrate Therapy in Mitochondrial Disease with lactic acidosis: an opel label clinical trial in MELAS and PHD deficiency patients
    Medical condition: Melas Syndrome and PDH deficency enchephalopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10053872 MELAS syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10053872 MELAS syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10062950 Leigh syndrome LLT
    Population Age: Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002502-74 Sponsor Protocol Number: NEU-01-02-01 Start Date*: 2012-02-14
    Sponsor Name:Neurophyxia B.V.
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled Phase II study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of 2-iminobiotin (2-IB) in neonates with gestational...
    Medical condition: Perinatal asphyxia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10004943 Birth asphyxia LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003500 Asphyxia neonatal LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-004158-23 Sponsor Protocol Number: 3303 Start Date*: 2005-04-15
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL ON THE USE OF ACETYL-L-CARNITINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    Medical condition: Amyotrophic lateral sclerosis therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004532-73 Sponsor Protocol Number: CC-5013-MM-019 Start Date*: 2007-02-07
    Sponsor Name:Celgene International Sàrl
    Full Title: A MULTICENTER, SINGLE-ARM, OPEN-LABEL EXPANDED ACCESS PROGRAM FOR LENALIDOMIDE PLUS DEXAMETHASONE IN PREVIOUSLY TREATED SUBJECTS WITH MULTIPLE MYELOMA
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001865-41 Sponsor Protocol Number: CC-5013-MM-015 Start Date*: 2007-03-27
    Sponsor Name:Celgene International Sàrl
    Full Title: A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) FR (Completed) DE (Completed) IE (Completed) CZ (Completed) AT (Completed) GB (Completed) DK (Completed) SE (Completed) IT (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 28 01:55:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA